<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098837</url>
  </required_header>
  <id_info>
    <org_study_id>NEAT 22/SSAT 060</org_study_id>
    <nct_id>NCT02098837</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)</brief_title>
  <official_title>An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the benefits of switching away from a kind of
      drug called a boosted protease inhibitor (PI) to a new drug called dolutegravir on patients'
      cardiovascular health (the health of their hearts). Patients are currently taking two other
      anti-HIV drugs, called nucleoside reverse transcriptase inhibitors (NRTIs), with their
      boosted PIs; these NRTIs will not be changed throughout the study. In order to compare the
      boosted PI and dolutegravir more accurately, half of study participants will be switched to
      dolutegravir immediately, and the other half will be switched after 48 weeks of continuing
      on the boosted PI.

      Boosted PIs are associated with increased heart and circulation risk so it is hoped that
      switching from a boosted PI to dolutegravir will improve the health of the patients' hearts.
      Dolutegravir is a drug for HIV treatment which has been approved for use in HIV patients in
      the US and Europe. Clinical trials using dolutegravir have found that it is effective at
      suppressing the HIV virus, and it  is at least as effective as the other drugs.

      This study will also investigate the safety (in terms of other side effects and the routine
      blood tests which the investigators ordinarily use to monitor patients' treatment) and
      monitor effectiveness, patients' viral load and CD4 counts, when patients switch treatment
      from a boosted PI to dolutegravir. Viral load is the amount of the HIV virus they have in
      their blood, and CD4 count is a measure of a type of cell that is in their immune system. We
      also aim to improve patients' cardiovascular health in general by providing them with
      information on how to live a healthy lifestyle (eg improving their diet, stopping smoking
      etc).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Virological suppression</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maintenance of virological suppression (ie HIV-1 RNA &lt;50 c/ml) after 48 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline in total cholesterol at week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological Suppression</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maintenance of virological suppression (ie HIV-1 RNA &lt;50 c/ml) at week 24 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count from baseline</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in CD4 count from baseline to week 24, 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline in total cholesterol</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline in total cholesterol at weeks 24 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to lipid values</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline to lipid values (LDL, HDL, triglycerides and TC:HDL ratio) and Framingham and DAD scores at weeks 24, 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety (clinical and laboratory adverse events) at weeks 24, 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers of inflammation</measure>
    <time_frame>48 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in markers of inflammation at baseline, week 48 and week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>24 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerability (EuroQoL questionnaire) at weeks 24, 48 and 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers of coagulation</measure>
    <time_frame>48 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in markers of coagulation at baseline, week 48 and week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers of endothelial dysfunction</measure>
    <time_frame>48 - 96 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in markers of endothelial dysfunction at baseline, week 48 and week 96</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Immediate switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Dolutegravir 50mg once daily</description>
    <arm_group_label>Immediate switch</arm_group_label>
    <arm_group_label>Deferred switch</arm_group_label>
    <other_name>Tivicay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient volunteers who meet all of the following criteria are eligible for this
             trial:

               1. Is male or female aged over 50, OR aged over 18 years with a Framingham risk
                  score above 10%

               2. Has documented HIV-1 infection

               3. Has signed the Informed Consent Form voluntarily

               4. Is willing to comply with the protocol requirements

               5. Has been receiving an ARV regimen containing a boosted PI (darunavir,
                  atazanavir, lopinavir, or fosamprenavir) plus 2NRTIs for &gt;24 weeks

               6. Has stable virological suppression (plasma HIV-RNA &lt;50 copies/mL for &gt;24 weeks)

               7. If female and of childbearing potential, is using effective birth control
                  methods and is willing to continue practising these birth control methods during
                  the trial and for at least 2 weeks after the last dose of study medication.
                  Note: Non-childbearing potential is defined as either post-menopausal (12 months
                  of spontaneous amenorrhoea and ≥45 years) or physically incapable of becoming
                  pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy

               8. If a heterosexually active male, he is using effective birth control methods and
                  is  willing to continue practising these birth control methods during the trial
                  and until follow-up visit

        Exclusion Criteria:

          -  Patients meeting 1 or more of the following criteria cannot be selected:

               1. Infected with HIV-2

               2. Using any concomitant therapy disallowed as per the reference safety information
                  and product labelling for the study drugs

               3. Has acute viral hepatitis including, but not limited to, A, B, or C

               4. Has chronic hepatitis B and/or C with AST and/or ALT &gt;5 x ULN Note:  Subjects
                  can enter trial with chronic HBV if HBV-DNA undetectable at screen (and no
                  detectable result in last 6 months) and with chronic HCV if not expected to
                  require treatment during the trial period.

               5. Any investigational drug within 30 days prior to the trial drug administration

               6. History of exposure to any ARVs other than PIs or NRTIs except if switch was for
                  tolerability/toxicity (NOTE: patients who have previously taken part in single
                  drug trials for less than 14 days need not be excluded, or for virological
                  failure with a genotypic resistance test without mutations

               7. Any prior evidence of primary viral resistance based on the presence of any
                  major resistance-associated mutation to backbone NRTI

               8. History of prior virological failure,eg 2 consecutive HIV-1 RNA &gt;50 c/ml -at or
                  after week 32 following first ART initiation or confirmed rebound viraemia &gt;200
                  copies/ml after having a VL of &lt;50 copies/ml without resistance test or with
                  significant mutations to any other ARV regimen (NOTE: Switch for toxicity or
                  tolerability with wild type virus does not count as virological failure)

               9. Dialysis or renal insufficiency (creatinine clearance &lt; 50ml/min)

              10. History of decompensated liver disease (AST or ALT≥5x the upper limit of normal
                  (ULN) or ALT ≥ )3 x ULN and bilirubin ≥ 1.5 x ULN with &gt; 35% direct bilirubin.

              11. Unstable liver disease (as defined by the presence of ascities, encephalopathy,
                  coagulopathy, hypoalbuminemia, esophagael or gastic varices, or persistent
                  jaundice), know biliary abnormalities (with the exception of Gilbert's syndrome
                  or asymptomatic gallstones))

              12. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh
                  classification

              13. If female, currently pregnant or breastfeeding

              14. Opportunistic infection within 4 weeks prior to first dose of DTG

              15. Clinical decision that a switch of antiretroviral therapy should be immediate

              16. Screening blood result with any grade 3/4 toxicity according to Division of AIDS
                  (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid
                  elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).

              17. Any condition (including illicit drug use or alcohol abuse) or laboratory
                  results which, in the investigator's opinion, interfere with assessments or
                  completion of the trial.

              18. History or presence of allergy to the study drug or their components
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Gatell, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish healthcare system</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice Shields</last_name>
    <phone>02033156101</phone>
    <email>alice.shields@chelwest.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Insititute Of Tropical Medicine Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>B-2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lida van Peterson</last_name>
      <email>lvpetersen@itg.be</email>
    </contact>
    <investigator>
      <last_name>Eric Florence, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kabamba Kabeya</last_name>
      <email>infectiousdiseases@stpierre-bru.be</email>
    </contact>
    <investigator>
      <last_name>Nathan Clumeck, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tessa James</last_name>
      <email>tessa.james@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Linos Vandekerckhove, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne Brochier</last_name>
      <email>corinne.brochier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Cotte, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales du CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herve Hue</last_name>
      <email>herve.hue@che-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Raffi, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Bichat Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Le Gac</last_name>
      <email>sylvie.legac@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Yeni, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasmine Dudoit</last_name>
      <email>yasminedudois@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Katlama, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samuel Ferret</last_name>
      <email>samuel.ferret@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel Molina, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Alicante</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Carlos</last_name>
      <email>f.carlosmenarquez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Felix Gutierrez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitario Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Livia Giner</last_name>
      <email>livginer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joaquin Portillo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IrsiCaixa</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordi Puig</last_name>
      <email>j.puig@flsida.org</email>
    </contact>
    <investigator>
      <last_name>Bonaventura Clotet, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nerea Rozas</last_name>
      <email>nrozas@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Daniel Podzamczer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pilar Callau</last_name>
      <email>pcallau@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Jose Gatell, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Pere Domingo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angel Lamas</last_name>
      <email>alm.lamas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Casado, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Miguel</last_name>
      <email>juanmi.castro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Gonzalez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elton John Centre</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicky Perry</last_name>
      <email>nicky.perry@bsuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Martin Fisher, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Jennings</last_name>
      <email>louise.jennings@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Gompels, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mortimer Market Centre</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Milinkovic</last_name>
      <email>a.milinkovic@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Laura Waters, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Sharp</last_name>
      <email>alice.sharp@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Julie Fox, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>Sw10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice Shields</last_name>
      <phone>02033156101</phone>
      <email>alice.shields@chelwest.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Graeme Moyle, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bart's Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Hand</last_name>
      <email>james.hand@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Chloe Orkin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Carroll</last_name>
      <email>anne.carroll2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Margaret Johnson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Legg</last_name>
      <email>k.legg@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alan Winston, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
